Ra Pharmaceuticals Inc (NASDAQ: RARX) is having an incredibly strong start to the trading session this morning, and for good reason. The company announced positive results from a Phase 2 clinical trial. As you could imagine, the news excited investors, sending the stock on a run for the top. Today, we’ll talk about:
- The data;
- what we’re seeing from RARX stock as a result; and
- what we’ll be watching for ahead.
RARX Announces Positive Top-Line Clinical Data
As mentioned above, Ra Pharmaceuticals is having a great day in the market this morning after the company announced positive top-line results from a clinical trial. The trial was the Phase 2 clinical trial that the company was using to evaluate zilucoplan for the treatment of generalized myasthenia gravis (gMG).
In the release, RARX said that the study achieved clinically meaningful and statistically significant reductions in both the primary and key secondary endpoints for both dose groups tested when compared to placebo at 12 weeks. In the release, the company said that Zilucoplan dosed at 0.3 mg/kg (SC) daily achieved a mean reduction from baseline of 6.0 points in the Quantitative Myasthenia Gravis score and a mean reduction from baseline of 3.4 points in the MG Activities of Daily Living score. Also, the company said that no patients treated with zilucoplan required rescue therapy.
In a statement, James F. Howard, MD, DProfessor of Neuromuscular Disease and Chief of the Neuromuscular Disorders Section at the Department of Neurology in the University of North Carolina School of Medicine, had the following to offer:
The rapid, profound, and sustained reductions in QMG and MG-ADL observed in this Phase 2 study confirm that complement inhibition was effective across a wide spectrum of MG patients in this study, whether refractory or non-refractory… Zilucoplan has the potential to become the first convenient, self-administered, complement inhibitor expanding access for patients living with this chronic, debilitating, neuromuscular disease.
The above statement was followed up by Nancy Law, CEO at the Myasthenia Gravis Foundation of America. Here’s what she had to offer with regard to the results released by RARX this morning:
This represents a potential breakthrough for all patients who are struggling every day with their MG, and seeking more effective and convenient treatment options… This unmet need was highlighted in a recent survey of patients from the MGFA database, where we learned that a majority of patients with MG are not satisfied with their current treatments and are interested in effective, at home, self-injectable treatment options.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to work in the market is that the news leads to moves. In the case of Ra Pharmaceuticals, the news proved to be overwhelmingly positive. After all, the strong clinical data means that the company is making progress when it comes to the development of Zilucoplan and suggests that the treatment will be moving into the next stages of development. So, it’s not surprising to see that excited investors are pushing the stock on a run for the top in the market this morning. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (8:40), RARX is trading at $17.70 per share after a gain of $1.24 per share or 7.53% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on RARX. In particular, we’re interested in following the continued development of Zilucoplan as the treatment is yielding overwhelmingly positive results. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!